- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04584762
Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine
Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine: a Prospective, Randomized, Double-blind, Parallel Group, Sham-controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized, sham-controlled, double-blind study for acute migraine attacks.
Treatment Phase:
• ≤60 days to present at clinic for treating up to 2 migraines (at least 48 hours apart). First treatment is randomized between active treatment and sham treatment. Second optional treatment is open-label.
Post-Treatment Follow-up Phase:
- 24 hours after initiating treatment, for each of up to two migraine treatments, for conducting post-treatment follow-up assessments of migraine symptoms.
- 30, 60, and 90 days following the first migraine treatment for migraine diary assessments (and MIDAS assessment at 90 days)
Collection of migraine diaries at 30, 60, & 90 days post enrollment. Collection of MIDAS data at 60 and 90 days post treatment.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85254
- Regen Pain and Wellness
-
-
Florida
-
Saint Petersburg, Florida, United States, 33701
- Murray Chiropractic Neurology
-
-
Missouri
-
Saint Charles, Missouri, United States, 63303
- StudyMetrix
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years of age at the time of the baseline visit.
- Episodic migraine with or without aura diagnosed according to the International Classification of Headache Disorders 3 beta diagnostic criteria.
- Migraine onset before the age of 50 years
- Migraine present for at least 1 year at the time of the Baseline Visit.
- Frequency of 1-12 migraine attacks per month in each of the 2 months prior to screening.
- Willingness, ability, and commitment to participate in baseline and follow-up evaluations without concurrent participation in another clinical trial.
- Signed patient informed consent form.
Exclusion Criteria:
- Prior or current diagnosis of migraine with brainstem aura, hemiplegic migraine, retinal migraine, migraine aura without headache, vestibular migraine.
- Use of acute headache medication within previous 48 hours of treatment visit (for each treatment visit).
- Use of acute medication for headache on >15 days per month in the 3 months prior to the Baseline Visit.
- Change in migraine preventive therapies or dosage within the preceding 1 month of Baseline Visit.
- Use of an opioid or barbiturate on more than 4 days per month in each of the 3 months prior to the Baseline Visit.
- Other primary headache disorder, other than tension-type headache on 3 or fewer days per month.
- History of secondary non-migraine headache disorders.
- Medical history of Meniere's disease; endolymphatic hydrops; loss of hearing in either ear that is either complete, requires a hearing aid, or has deteriorated noticeably over the past year; ear surgery (including ear tubes); chronic continuous or current tinnitus; superior canal dehiscence.
- Discomfort, infection, or other abnormal symptoms or disorders of either ear within 1 month prior to the enrollment Screening or Treatment Visit.
- Pregnant or trying to become pregnant.
- Unable to provide informed consent.
- Inability to present to the medical clinic for study treatment during a migraine attack.
- Unable or unlikely to follow instructions for proper use of the device.
- Presence of any condition or state that would prevent the subject from sitting or lying down during the course of the treatment (up to 30 minutes).
- History of receiving ear pressure therapy (insufflation) to treat any condition.
- Personal or family affiliation as a service provider (e.g. employee, contractor, consultant, or volunteer) with a migraine treatment device company other than the study sponsor.
- Perforated or compromised tympanic membrane, and which is confirmed by otoscope inspection by the Investigator before or upon presentation of the subject for the Treatment Visit.
- Any other information about the subject's medical condition that, in the reasonable professional judgement of the Investigator, may adversely affect the intended safety or results of the treatment as intended and as a reasonable basis to exclude the subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Sham treatment
The AVPI device software is set in "sham mode" which does not deliver the therapy to the subject.
Neither the subject or the investigator is aware of which mode is being used.
|
Acute migraine treatment
|
Experimental: Active Treatment
The AVPI device software is set in "active mode" which delivers the therapy to the subject.
Neither the subject or the investigator is aware of which mode is being used.
|
Acute migraine treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Freedom Rates - active
Time Frame: 2 Hours post treatment
|
Pain freedom rates (PFR)
|
2 Hours post treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: David George, Nocira, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NC05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Headache
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
-
Ariston Pharmaceuticals, Inc.UnknownMigraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With AuraFinland, Netherlands, United Kingdom
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Danish Headache CenterCompletedHeadache, Migraine | AuraDenmark
-
Nanfang Hospital, Southern Medical UniversityBrainClos Co., LTD.; Zhuhai Fudan Innovation InstituteNot yet recruitingCluster Headache | Migraine in Children | Tension Headache | Migraine in Adolescence | Primary HeadacheChina
-
Danish Headache CenterCompletedMigraine Headache | Migraine Without AuraDenmark
-
Children's Hospital Medical Center, CincinnatiPatient-Centered Outcomes Research InstituteRecruitingMigraine | Migraine Disorders | Headache | Headache Disorders | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
-
Behar, Caren, M.D.UnknownMigraine | Migraine Disorders | Migraine Headache | Acute MigraineUnited States
Clinical Trials on Automated Variable Pressure Insufflation
-
Federico II UniversityUnknownWeaning From Mechanical VentilationItaly
-
Selcuk UniversityCompletedAbdominal Compartment SyndromeTurkey
-
Johns Hopkins UniversityTerminatedAcute Myocardial InfarctionUnited States
-
Konkuk University Medical CenterNot yet recruiting
-
Tan Tock Seng HospitalNgee Ann Polytechnic SingaporeCompletedStroke | Hemiplegic GaitSingapore
-
University of North Carolina, Chapel HillCompletedSepsis | Systemic Inflammatory Response SyndromeUnited States
-
Yale UniversitySurgiQuest, Inc.Completed
-
Bordeaux Colorectal Institute AcademyRecruitingColorectal Surgery | Benign or Malignant Rectal or Colon TumorsFrance
-
ResMedRoyal Brompton & Harefield NHS Foundation TrustCompletedNeuromuscular Disease | Chest Wall Disorder | Nocturnal HypoventilationUnited Kingdom
-
University Hospital, BordeauxActive, not recruitingKidney Tumors Treated With Minimally Invasive SurgeryFrance